TAFLUPROST

Search structure
Trade Names:
Synonyms:
Status: Approved (2012)
Entry Type: Small molecule
Molecule Category: UNKNOWN Prodrug
ATC: S01EE05
UNII: 1O6WQ6T7G3

Structure
InChI Key WSNODXPBBALQOF-VEJSHDCNSA-N
Smile CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COc1ccccc1
InChI
InChI=1S/C25H34F2O5/c1-18(2)32-24(30)13-9-4-3-8-12-20-21(23(29)16-22(20)28)14-15-25(26,27)17-31-19-10-6-5-7-11-19/h3,5-8,10-11,14-15,18,20-23,28-29H,4,9,12-13,16-17H2,1-2H3/b8-3-,15-14+/t20-,21-,22+,23-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C25H34F2O5
Molecular Weight 452.54
AlogP 4.68
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 12.0
Polar Surface Area 75.99
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 32.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Prostanoid FP receptor agonist FDA
Primary Target
FP receptor

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Glaucoma 4 D005901 ClinicalTrials
Glaucoma, Open-Angle 4 D005902 ClinicalTrials
Ocular Hypertension 4 D009798 ClinicalTrials

Related Entries

MCS

Scaffolds

Side Effects from Label

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Eye disorders
37.42
Nervous system disorders
12.53
General disorders and administration site conditions
9.73
Skin and subcutaneous tissue disorders
6.67
Respiratory, thoracic and mediastinal disorders
4.89
Injury, poisoning and procedural complications
3.71
Gastrointestinal disorders
3.01
Vascular disorders
2.74
Immune system disorders
2.47
Infections and infestations
2.42
Cardiac disorders
2.15

Cross References

Resources Reference
CAS NUMBER 209860-87-7
ChEBI 66899
ChEMBL CHEMBL1963683
DrugBank DB08819
DrugCentral 4229
FDA SRS 1O6WQ6T7G3
Human Metabolome Database HMDB0015704
Guide to Pharmacology 7451
PubChem 9868491
SureChEMBL SCHEMBL1286148
ZINC ZINC000013912394
CONTENTS